O1 Hepatitis C: the treatment landscape in 2017
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Hepatitis C virus (HCV) therapeutic development, with highly curative well tolerated all oral direct-acting antiviral (DAA) regimens, is one of the major advances in clinical medicine in recent decades. Australian Government subsidisation of DAA regimens through the Pharmaceutical Benefits Scheme (PBS) since March 2016, and the broad eligibility for access (all adults with chronic HCV infection, no prescriber restrictions other than prescriber to specialist consultation for inexperienced prescribers), provides the foundation for rapid DAA scale-up, major individual and population-level impacts, and elimination of HCV as a public health threat over the next decade.

Over the period March--December 2016 an estimated 32,400 people initiated DAA therapy, representing 14% of the estimated 230,000 people living with chronic HCV infection. Importantly, in the context of the WHO elimination target of 65% reduction in liver-related mortality by 2030, an estimated 70% of people living with HCV-related cirrhosis have received DAA therapy (including through pre-PBS listing compassionate access programs). Preliminary evidence also suggests relatively high DAA uptake (comparable or higher than the broader HCV population) among people who currently inject drugs (PWID).

Key trends during 2016 in relation to DAA therapy initiation included younger age distribution and higher proportions of prescribing by general practitioners, reflecting the expansion of HCV treatment access beyond large specialist centres. A range of models of HCV care are being developed and implemented, including higher throughput tertiary care (enabled by more simplified treatment monitoring and limited toxicity-based care), nurse-led care (both in community and prison settings), drug and alcohol service-based care, and primary and community health clinic care.

The addition of new DAA regimens during 2017--2018, in particular sofosbuvir/velpatasvir and glecaprevir/pibrentasvir with pangenotypic efficacy, and short treatment duration (8--12 weeks), will further enhance broadened access and support diverse models of care. DAA treatment assessment and monitoring is likely to be further simplified, with qualitative HCV RNA detection potentially replacing HCV viral load and genotype evaluation, and the predictable virological responses and minimal toxicity leading to removal of on-treatment monitoring.

Despite the potential broad DAA access in Australia, early evidence indicates declining DAA initiations in 2017 compared to 2016. Further efforts are required to continue high DAA uptake, particularly for marginalised populations including current PWID and prisoners. Community awareness campaigns could facilitate enhanced HCV screening and DAA uptake for former PWID and those from other risk groups (e.g. immigrant populations from high HCV prevalence settings).

O2 JoinJade: a culturally and linguistically tailored campaign to help end hepatitis B
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An estimated 257 million people in the world are living with chronic hepatitis B infection (CHB) resulting in almost 900,000 deaths in 2015 from cirrhosis and liver cancer. Most of them were infected from vertical or horizontal transmission at an early age when they were most vulnerable to develop chronic infection. The prevalence of CHB is highest in people who are living or were born in Africa, Asia and Pacific region including indigenous Australians. In the U.S., the high prevalence of CHB in foreign-born Asians and Pacific Islander Americans is among the greatest health disparity in the country [@jve1_27-bib-0001].

The National Academy of Sciences, Engineering and Medicine was commissioned by the U.S. CDC and Health and Human Services to determine the feasibility, barriers and recommendations to eliminate hepatitis B and C. The two-part report released in 2016 and 2017 concluded that elimination of hepatitis B as a major public health problem in the U.S. is feasible by ending transmission with vaccination, reducing complications of CHB by early diagnosis, linkage to monitoring and treatment, and eliminating disease stigma [@jve1_27-bib-0002]. The report estimated that a 50% reduction in mortality from CHB is feasible by 2030 if diagnosis and treatment rates are increased to 90% and 80% respectively. To reach the 2030 goals, the report recommended the establishment of performance measures to monitor compliance with national hepatitis B screening and hepatitis birth dose vaccination guidelines by healthcare organizations and physicians, and to increase the capacity to treat CHB in primary care and set up referral systems for medically complex patients.

Among the major barriers to elimination is poor hepatitis B and liver cancer knowledge, attitude and practices among healthcare providers and the high prevalence ethnic populations resulting in missed opportunities for prevention, screening and treatment [@jve1_27-bib-0001]. JoinJade or Jade Ribbon is a culturally and linguistically tailored campaign modelled after the Red Ribbon to brand the fight to end hepatitis B and hepatitis B discrimination worldwide [@jve1_27-bib-0005]. By fostering public-private partnership, political and celebrity support, Jade Ribbon reaches out to the high prevalence ethnic populations through culturally and linguistically appropriate multimedia messaging and community events to promote hepatitis B facts, screening, vaccination, long-term monitoring and treatment. A growing number of multinational companies have JoinJade to raise awareness, protect employees and their families from hepatitis B and liver cancer, and end workplace hepatitis B discrimination worldwide.

O3 HCV elimination program in Georgia: successes and challenges
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Introduction {#jve1_2-sec-0001}
============

On April 28, 2015, in collaboration with CDC, Gilead Sciences and other partners, Georgia launched a comprehensive, national HCV elimination program that included free of charge treatment for all HCV infected persons. Unified treatment database was created where patients socio-demographic and clinical data are entered for all patients included in the program. 5 year elimination plan was developed and external Technical Advisory Group (TAG) was established. Country\'s targets for the cascade of HCV care are 90-95-95. That is, diagnose 90% of HCV infected adults, treat 95% of those diagnosed, and cure 95% of those treated.

Patients with advanced liver fibrosis (≥F3 by elastography or \>3.25 by FIB score) were prioritized at the beginning of the program and the regimens used were sofosbuvir/ribavirin with or without interferon. The eligibility as well as treatment regimen was later expended (sofosbuvir/ledipasvir combination was added). By December 31, 2017, 36 322 HCV RNA positive patients started treatment, 27 595 completed the course, 19 778 are under ongoing treatment, 537 have not completed treatment. For patients treated with sofosbuvir/ribavirin regimen with or without interferon the sustained viral response (SVR) rate was 80% with 98.2% SVR rate among patients treated with sofosbuvir/ledipasvir with or without ribavirin.

The key challenges of the program are: 1. Decreasing number of the patients enrolled in elimination program; 2. Unknown effectiveness of linkage to care. The next steps of the program are planning activities to identify HCV cases who did not know their infection status and enroll in the program; To expand the treatment services to harm reduction and primary care centers and improve monitoring of linkage to care.

O4 Outcomes of treatment for hepatitis C virus infection in the prison setting
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Background {#jve1_3-sec-0001}
==========

The prison setting provides opportunity to engage and treat high-risk individuals to reduce HCV prevalence and incidence. There has been little data to support the efficacy of prison-based treatment programs using DAAs. A nurse-led hepatitis program has been implemented in 14 prisons in Victoria to assess and treat prisoners living with HCV. We have evaluated the efficacy of antiviral therapy delivered in the prison system using this model.

Methods {#jve1_3-sec-0002}
=======

All prisoners are offered screening for viral hepatitis on prison entry. Seropositive prisoners are referred for protocol-driven face-to-face (F2F) assessment by a Clinical Nurse Consultant (CNC) at their local prison. CNCs conduct clinical assessments and liver stiffness measurement using transient elastography (FibroScan). Patients can be triaged for consultation by supervising hepatologists. Eligible prisoners must be able to complete treatment within expected sentence duration. DAA therapies are prescribed by supervising hepatologists based on the protocol-driven assessments. We report the results of the first 17 months of the program.

Results {#jve1_3-sec-0003}
=======

1180 prisoners have been assessed, 718 have been eligible for treatment, 633 prisoners have had treatment commenced and 244 have reached the SVR12. 87% were male, 13% were female. Genotype 3a HCV accounted for 46%, Genotype 1a HCV=46%. 37% had advanced fibrosis, 23% were cirrhotic. 46% have been prescribed Sofosbuvir/Daclastasvir, 46% Sofosbuvir/Ledipisvir, 6% other. Per-protocol analysis SVR12 cure rate of 95%, intention-to-treat analysis 68%. There were 4 relapses, 2 reinfections and 2 deaths. Results of all prisoners completing treatment before 1^st^ August 2017 will be presented at conference.

Conclusion {#jve1_3-sec-0004}
==========

Treatment for HCV can be delivered safely, effectively and in high numbers in the prison setting using an innovative nurse-led model of care. The prison setting provides an excellent opportunity to engage and treat high risk individuals, and should be part of public health platforms supporting elimination of HCV.

Disclosure of interest statement {#jve1_3-sec-0005}
================================

The initiative represents a partnership between the Hospital Gastroenterology Department and the Department of Justice and Regulation, State Government of Victoria.

O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective
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Background {#jve1_4-sec-0001}
==========

Gay and bisexual men (GBM) are the key population affected by HIV and hepatitis C coinfection in Australia. The co-EC Study supports general practitioners to initiate treatment in primary care settings, aiming to show that treatment scale-up can eliminate HCV in coinfected GBM. We report on the feasibility of this model-of-care based on preliminary treatment outcomes.

Methods {#jve1_4-sec-0002}
=======

The co-EC Study is an ongoing (March 2016--) clinician-directed, open-label trial of treatment among people with HIV/HCV coinfection. HCV testing and treatment are delivered by specialists or general practitioners with nursing support at tertiary (n=2) and primary care (n=4) sites in Melbourne. Nurses deliver education, treatment support and coordinate visits.

Enrolment involves routine clinical data (haematological, biochemical, fibrosis assessment), which may prompt a specialist to be consulted for advice or referral prior to treatment initiation, and participants complete a self-reported behavioural survey. The primary outcomes of this preliminary analysis are treatment uptake and sustained virological response (SVR12).

Results {#jve1_4-sec-0003}
=======

As of January 2017, 160 participants had enrolled (99% male; median age 48), including 106(**66%**) **seen in primary care. Based on clinic data**, 40(38%) could commence treatment immediately, 25(24%) required specialist advice, 17(16%) required specialist referral, and 22(21%) had incomplete data. Overall, 136(85%) participants have commenced treatment (sofosbuvir/daclatasvir-50%; sofosbuvir/ledipasvir-47%).

High-risk behaviours were commonly reported at enrolment, including: ever injecting drugs (62%), of whom 33% reported ever injecting with a used needle/syringe; past month recreational drug use (50%); and in the previous six months, group sex (27%) and inconsistent condom use among those with casual male sex partners (79%).

Of fifty-six participants assessed 12-weeks post-treatment, and where HCV RNA was available (n=50), 100% achieved SVR12.

Conclusions {#jve1_4-sec-0004}
===========

Treatment of HIV/HCV co-infected men in primary care settings is feasible, highly effective and may lead to sustained increases in treatment uptake and HCV elimination in this population.

Disclosure of interest statement {#jve1_4-sec-0005}
================================

The co-EC Study received investigator-initiated research funding support from Bristol Myers Squibb

O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study
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Background {#jve1_5-sec-0001}
==========

HCV transmission is high in prisons. The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study in New South Wales, Australia consists of two major phases: i)Surveillance, HCV status and risk behaviour are evaluated at study entry and monitored longitudinally; ii)Treatment scale-up, participants with detected HCV-RNA are offered sofosbuvir/velpatasvir. This analysis assessed HCV incidence in two SToP-C maximum-security prisons before treatment scale-up.

Methods {#jve1_5-sec-0002}
=======

Surveillance phase data of participants enrolled during October 2014--November 2016 with at least one follow-up visit was used. Participants were screened for HCV-antibody (Ab) and HCV-RNA at enrolment. HCV-Ab or HCV-RNA negative participants were tested every six months. Those with HCV-Ab negative and HCV-Ab positive/HCV-RNA negative were considered at risk of HCV primary infection and reinfection, respectively.

Results {#jve1_5-sec-0003}
=======

Among 748 participants screened, 171 were included in analysis (122 and 49 were at risk of HCV primary infection and reinfection, respectively; Median age 36 years; median duration of stay at the prison 4 years). During 178 person-years (py) of follow-up, 9 incident infections were observed, including 5 primary and 4 reinfections. HCV incidence was 5.1/100 py (95%CI: 2.6--9.7). All 9 participants with incident HCV reported ever injecting drug use (IDU), and 5 reported IDU in the past month in prison. Among those reporting ever IDU, overall HCV incidence was 13.0/100 py (95% CI: 6.8--25.0); primary infection incidence was 18.6/100 py (95% CI: 7.7--44.7); and reinfection incidence was 9.4/100 py (95% CI: 3.5--25.1). Among those reporting IDU in the past month, HCV incidence was 35.5/100 py (95% CI: 14.8--85.3), while all participants with incident HCV (n=5) reported sharing needle/syringe.

Conclusion {#jve1_5-sec-0004}
==========

High HCV incidence was found in SToP-C maximum-security prisons, supporting the need for comprehensive prevention strategies, including harm reduction and a HCV treatment-as-prevention evaluation. HCV transmission was primarily associated with IDU, particularly recent IDU in prison.

Disclosure of interest statement {#jve1_5-sec-0005}
================================

This research was supported in part by Gilead Sciences, Inc. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Gilead Sciences, Inc. The research was also supported by the Australian Government Department of Health and Ageing through a National Health and Medical Research Council (NHMRC) Partnership Project Grant (APP1092547). The contents of the published material are solely the responsibility of the individual authors and not do not reflect the views of NHMRC.

O7 Moving towards HCV elimination in HIV/HCV co-infection in Australia following universal access to interferon-free therapy
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Introduction {#jve1_6-sec-0001}
============

HCV elimination among people with HIV/HCV co-infection may be possible in Australia, given population size, high proportion diagnosed and linked to care, and unrestricted access to direct-acting antiviral (DAA) therapy. The aim of this analysis was to assess HCV treatment uptake and outcomes among HIV/HCV co-infected adults enrolled in the Control and Elimination of HCV from HIV-infected individuals within Australia (CEASE-D) cohort study following the availability of DAA therapy.

Methods {#jve1_6-sec-0002}
=======

Cumulative HCV treatment uptake was defined as the proportion of individuals with detectable HCV RNA at enrolment who initiated HCV treatment during follow-up (July 2014--March 2017). Clinical and demographic factors associated with treatment uptake were evaluated by logistic regression analysis. Sustained virological response was assessed in individuals who had completed 12 weeks post treatment follow-up (SVR12) at the time of analysis.

Results {#jve1_6-sec-0003}
=======

A total of 412 HIV/HCV antibody-positive individuals were enrolled, of whom 95% were male, 13% had cirrhosis, and 22% had ever received interferon-based therapy. The principal modes of HCV transmission were injection drug use (54%) and sexual exposure in men-who-have-sex-with-men (28%). HCV RNA was detected in 78% (n=317), with genotype 1 (62%) and 3 (27%) predominant.

Cumulative HCV treatment uptake among individuals with detectable HCV RNA was 67% (n=211; 95%CI 62--72%), with a marked increase in annual treatment uptake in 2016 (66%, 95%CI 60--71%) as compared with 2014 (4%, 95%CI 1--12%) and 2015 (8%, 95%CI 5--13%) (p\<0.001). Sofosbuvir/ledipasvir (51%) and sofosbuvir+daclatasvir (38%) were most frequently prescribed. No clinical or demographic factors, including current high-risk drug and sexual behaviour, were associated with HCV treatment uptake.

Among 159 individuals with follow-up post treatment, SVR12 was 96%, with one case of reinfection following SVR.

Conclusion {#jve1_6-sec-0004}
==========

Broad unrestricted access to government-subsidised DAA therapy has permitted rapid treatment scale-up with high uptake and efficacy among people with HIV/HCV co-infection.

Disclosure of interest statement {#jve1_6-sec-0005}
================================

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Burnet Institute receives funding from the Victorian Operational Infrastructure Support Program. Research reported in this publication was supported by Gilead Sciences Inc as an investigator-initiated study. The content is solely the responsibility of the authors. Gregory Dore, Margaret Hellard and Gail Matthews are supported by the National Health and Medical Research Council (GD: Practitioner Fellowship; MH: Principal Research Fellowship; GM: Career Development Fellowship).

O8 Optimal liver cancer surveillance in the community: do recall and reminder systems hold the answer?
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Background {#jve1_7-sec-0001}
==========

Liver cancer surveillance with regular ultrasound scans reduces mortality in chronic hepatitis B(CHB) but is difficult to achieve in clinical practice. From 2012--2016 a community health centre was supported by external hepatitis B nurses to improve CHB care with an audit, phone calls and mailed reminders to patients.

This study aimed to describe adherence to liver cancer surveillance in eligible patients, and determine the impact of the support and resources of an external service in improving adherence.

Methods {#jve1_7-sec-0002}
=======

Two cross sectional audits of clinic attendees with CHB and eligible for liver cancer surveillance were conducted over of a 4.5-year period (2012--2016). Participation was defined as two consecutive scans and \>1 scan every 2 years. Adherence was classified as poor (\<1 scan per 14 months), sub optimal (average of one every 14 months) and optimal (average of 2 every 14 months). Data were also collected regarding frequency of viral load test ordering, and any significant illness or reason for a period of non-attendance, if recorded.

Results {#jve1_7-sec-0003}
=======

67 patients had liver cancer surveillance, representing 213 person-years, and a participation rate of 74.63%. The median age was 37.61 years (interquartile range 28.60--50.24); the majority (64.2%) were born in the African region, and 5 (7.5%) had cirrhosis. The proportion of patients who had received a scan in the previous 7 months increased fivefold from 9.5% at baseline to 55.6% at final audit (p\<0.001). Ordering of ultrasounds at least every 12 months occurred in 60 (89.55%), however optimal adherence was only observed in 18 patients (26.87%), while 29 (43.28%) had suboptimal adherence and 20 (29.85%) poor adherence.

Conclusion {#jve1_7-sec-0004}
==========

It is difficult to achieve optimal adherence even with additional support and comprehensive recall and follow-up. Further exploration of barriers to liver cancer surveillance including knowledge and health system related barriers need to be explored.

Disclosure of interest statement {#jve1_7-sec-0005}
================================

The authors have no conflicts of interest to declare

O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies
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Background {#jve1_8-sec-0001}
==========

Prior to direct-acting antiviral (DAA) therapy, \~1--2% of people who inject drugs (PWID) were treated for HCV annually in Australia. This study examined HCV treatment uptake and associated factors among PWID in October 2016, seven months after DAA therapies were listed on the Pharmaceutical Benefits Scheme.

Methods {#jve1_8-sec-0002}
=======

The Australian Needle Syringe Program Survey (ANSPS) is cross-sectional sero-surveillance project conducted annually. Participation involves self-completion of a behavioural questionnaire and provision of a dried blood spot for HIV/HCV serological testing. Recent (last 12 months) treatment uptake was estimated among HCV antibody positive respondents after adjusting for cleared infection (−25% for spontaneous clearance and −55% for prior treatment-induced clearance). Multivariable logistic regression examined factors associated with recent treatment uptake.

Results {#jve1_8-sec-0003}
=======

Among n=1,019 antibody positive respondents and after adjusting for cleared infection, 20% (n=143) of respondents reported recent treatment uptake in 2016. Respondents who reported spontaneous clearance (n=104) or prior treatment induced clearance (n=31) were excluded. Factors independently associated with recent treatment among remaining respondents (n=884, 69% male, median age 42 years) included: older age (36--45 yrs AOR 1.84, 95% CI 1.02--3.31, p=0.042; \>45 yrs AOR 3.37, 95% CI 1.90--5.95); current opioid substitution therapy (AOR 1.92, 95% CI 1.31--2.81) and \<daily injection (AOR 1.88, 95% CI 1.28--2.76, p=0.001). Notwithstanding higher treatment uptake among respondents who injected \<daily (21%), one in ten (11%) respondents who injected daily or more frequently reported recent treatment. Five of ten HIV/HCV co-infected respondents reported recent treatment (AOR 6.51, 95% CI 1.76--24.07, p=0.005).

Conclusions {#jve1_8-sec-0004}
===========

This study is the first to demonstrate a rapid and significant increase in HCV treatment among PWID following broad access to DAA therapies. Assuming successful treatment in the majority of cases, the pool of active HCV infection among Australian PWID may have declined by up to 20% within the first 12 months of availability of DAA therapy.

Note: HCV RNA testing is underway but currently incomplete. Existing estimates for spontaneous and treatment induced clearance and the pool of active infection will be updated with serologically confirmed data if this abstract is accepted.

Disclosure of interest statement {#jve1_8-sec-0005}
================================
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O10 Treatment of Aboriginal and Torres Strait Islander clients with direct acting antivirals at the Kirketon Road Centre
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Introduction {#jve1_9-sec-0001}
============

The Kirketon Road Centre (KRC) is a publicly-funded targeted primary health care service in Kings Cross, Sydney. KRC provides prevention, treatment and care of viral hepatitis for people who inject drugs, sex workers, and 'at-risk' young people. KRC operates an Aboriginal program with dedicated Aboriginal staff both on-site and at outreach locations with Aboriginal partner organisations delivering both Aboriginal health promotion, and direct clinical care. The aim of this study was to describe the demographic characteristics and treatment outcomes of Aboriginal clients treated for hepatitis C (HCV) with direct acting antiviral (DAA) therapy at KRC.

Methods {#jve1_9-sec-0002}
=======

Data were collected from health records of Aboriginal clients with HCV attending KRC during 2016, including those treated with DAAs. Data were compared between Aboriginal and non-Aboriginal clients who were assessed for DAAs and of those who commenced treatment.

Results {#jve1_9-sec-0003}
=======

Of the 194 clients assessed for treatment in 2016, 47 (24%) identified as Aboriginal. Of those, 34 (72%) commenced treatment. Median age was 43, 74% were male, 34% were homeless in the last 12 months, 87% were unemployed, 88% had a history of imprisonment, 29% had ever sex worked, and 71% injected in the last 6 months. Eighty percent (80%) of these clients were on OST, with 69% receiving OST at KRC. Nine percent were co-infected with HIV and 18% had a Fibroscan score indicating cirrhosis. Twenty-three (49%) are 12 weeks post treatment with 20 (87%) having been tested, of whom all (100%) were cured. A higher proportion of Aboriginal clients assessed for DAAs initiated treatment (72%) compared to non-Aboriginal clients (86/147, 59%).

Conclusion {#jve1_9-sec-0004}
==========

KRC\'s model of care endeavours to ensure equity of access to care for Aboriginal clients. Despite high levels of social marginalisation, successful treatment outcomes were achieved. This study describes a progressive approach toward ensuring HCV elimination is equally achievable this population.

Disclosure of interest statement {#jve1_9-sec-0005}
================================

The authors have no conflicts of interest to declare.

O11 Hepatitis C: stigma indicators and patient reported outcome measures for DAA treatment
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Introduction {#jve1_35-sec-0001}
============

People living with hepatitis C (PLHCV) and people who inject drugs (PWID) commonly report experiencing stigma and discrimination, which can act as a barrier to health care access and treatment. This presentation will report on two projects (1) a national system to monitor experiences of stigma and discrimination among PLHCV and PWID; (2) "patient reported" experiences and outcomes of DAA treatment for PWID to examine factors beyond "cure" which could impact on treatment goals.

Methods {#jve1_35-sec-0002}
=======

\(1\) an online survey which measured experiences of stigma and discrimination using a brief indicator developed for this project; (2) Semi-structured interviews (n=24) were conducted with four groups of PWID who live with HCV: (i) people who are considering DAA treatment; (ii) people who are currently undertaking DAA treatment; (iii) people who have completed DAA treatment (6-12 months post-treatment); (iv) people who have refused or delayed DAA treatment.

Results {#jve1_35-sec-0003}
=======

\(1\) Among 153 PLHCV and PWID, past 12 month experiences of stigma and discrimination is common in relation to injecting drug use (54%) and hepatitis C (50%), 49% reported being treated negatively or differently to other people by health workers; (2) The outcomes of treatment noted as important by participants included: physical effects (less fatigue and feeling "more enthusiastic about life"); social connections (being able to consider intimate relationships and feeling more relaxed about HCV risk in interactions with family); and, changes in identity (feeling relieved to lose the HCV "label" as well as feeling "lost" without this identity). Provision of information was patchy, especially regarding post-treatment care.

Conclusion {#jve1_35-sec-0004}
==========

Ongoing monitoring of stigma is important to identifying changes in trends over time and potential strategies to reduce experiences of stigma and discrimination. Factors beyond cure need to be considered in monitoring the experience and outcomes of HCV DAA treatment for people who inject drugs.

Disclosure of interest statement {#jve1_35-sec-0005}
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O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued
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Background {#jve1_11-sec-0001}
==========

In 2015, of 227,000 people living with chronic HCV in Australia, an estimated 32,400 people initiated direct acting antiviral (DAA) treatment in 2016. We estimated the future impact of this DAA program in reducing the prevalence, transmission, and morbidity of chronic HCV to evaluate whether Australia can meet WHO HCV elimination targets.

Methods {#jve1_11-sec-0002}
=======

We used a mathematical model and assumed three different future treatment coverage scenarios over 2016--2030: *optimistic*, 30,000 continues each year 2016--2030; *intermediate*, treatment numbers drop moderately: 30,000 (2016), 26,000 (2017), 21,000 (2018), then 17,000 (2019--2030); and *pessimistic*, treatment drops markedly; 30,000 (2016), 17,000 (2017), 13,000 (2018), then 13,000 (2019--2030), with comparison to a status-quo scenario where treatment remains at 2015 levels (7,300). Treatment rates initially varied by disease stage (higher for advanced fibrosis), but were assumed uniform across HCV transmission risk level sub-populations.

Results {#jve1_11-sec-0003}
=======

By 2030, we estimate the intermediate DAA treatment scenario would avert 37,950 (30,510--45,950) new HCV infections, 10,350 (7,000--12,810) liver-related deaths, and 11,990 (9,640--13,790) HCC cases, equating to a 100% (82--100%), 52% (42--63%) and 64% (43--79%) reduction. The model estimates that under the intermediate scenario Australia will meet WHO targets of 80% of eligible people on treatment by the year 2027, 90% reduction in annual incidence by the year 2028, and 65% reduction in annual liver-related deaths by the year 2025. The pessimistic scenario will delay meeting the targets by 4--5 years, and the optimistic scenario will bring it forward by 3--5 years.

Conclusion {#jve1_11-sec-0004}
==========

Based on a realistic uptake scenario Australia should meet the WHO HCV elimination targets in 10--13 years, even with a moderate reduction of DAA treatment uptake. Achieving these targets requires treatment access for high risk HCV transmission populations, in conjunction with current harm reduction activities and HCV testing strategies.
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O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study
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Introduction {#jve1_12-sec-0001}
============

Interferon-free direct-acting antiviral therapy (DAA) is safe and effective in people with hepatitis C virus (HCV) receiving stable opioid substitution therapy (OST), but there are little data among recent people who inject drugs (PWID). Improved evidence of DAA outcomes among recent PWID is crucial for elimination efforts, given the potential impact of HCV treatment as prevention. The aim of this study was to evaluate the efficacy and safety of sofosbuvir/velpatasvir for chronic HCV among recent PWID.

Methods {#jve1_12-sec-0002}
=======

SIMPLIFY is an international open-label study that recruited participants with recent injecting drug use (previous six months) and chronic HCV genotype (G) 1--6 infection between March and October, 2016 in seven countries (19 sites). Participants received sofosbuvir/velpatasvir daily administered in a one-week electronic blister pack (records the time and date of each dose) for 12 weeks. The primary endpoint was sustained virological response at 12 weeks (SVR) after the end of therapy.

Results {#jve1_12-sec-0003}
=======

Of 103 participants who initiated treatment (mean age 47 years; 72% male; 9% cirrhosis), 35% had HCV G1, 5% G2, 58% G3, and 2% G4. At screening, 57% were receiving OST, with 74% injecting in the past month, 48% at least once a week. Overall, 96% (99/103) completed treatment. There were four discontinuations (loss to follow-up, n=3; overdose death, n=1). End of treatment response (ETR) was 96% (99/103). Overall, two participants with an ETR did not have SVR12 \[loss to follow-up, n=1; virological relapse/reinfection, n=1 (undergoing sequencing to confirm)\]. In intent-to-treat analyses among all participants, SVR12 was 94% (97/103).

Conclusion {#jve1_12-sec-0004}
==========

In this study of once-daily sofosbuvir/velpatasvir among people with recent injecting drug use and chronic HCV, high treatment completion, and SVR were observed, with no cases of virological failure and one case of virological relapse/reinfection. This supports DAA therapy in recent PWID, a key population for HCV elimination strategies.

O14 Community prescribing of hepatitis C treatment: a mentorship and capacity building model to increase treatment uptake by targeted populations
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Background {#jve1_13-sec-0001}
==========

Accessibility of hepatitis C (HCV) direct acting antiviral (DAA) treatment has presented an unparalleled opportunity in Australia to achieve elimination of HCV as a public health concern. The significant early uptake of treatments largely arose from tertiary settings has subsequently declined. Community-based prescribing is slowly evolving but needs to be augmented using initiatives that support services to include HCV treatment within their existing frameworks. The Integrated Hepatitis C Service (IHCS) at Melbourne Health partnered with community services providing capacity development and mentorship programs, reaching targeted populations including regional/rural Victorians and people experiencing homelessness in Central Melbourne.

Method {#jve1_13-sec-0002}
======

The IHCS, partnered with a regional community health service and Gastroenterologist in Wodonga to develop centrally triaged HCV treatment clinics onsite and via telehealth. Education, remote consultation and telephone support provided by this team facilitated General Practitioner (GP) prescribing. In metropolitan Melbourne, the IHCS Clinical Nurse Consultant (CNC) provided clinical support and mentorship to the nurse at a homeless person\'s crisis accommodation centre and a local GP, to establish a HCV treatment pathway for the residents.

Results {#jve1_13-sec-0003}
=======

The regional Victorian partnership effectively eliminated a wait list of 275 people requiring HCV treatment. Since DAA\'s have been available 192 have commenced treatment via this model. The IHCS received 57 remote consultation requests from GP\'s in this region with a commencement rate of \>80%. The homeless person\'s service provided HCV assessment for 30 clients and supported 10 to commence treatment prescribed by a local GP.

Conclusions {#jve1_13-sec-0004}
===========

HCV treatment models embedded within clients' existing services or without geographical constraints are unique in their requirements of support and integration. In the shift from tertiary treatment to community prescribing, essential in maintaining the momentum towards elimination targets, tertiary services are ideally placed to support workforce development along with ongoing mentorship, instrumental in increasing uptake of treatment.
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Background {#jve1_14-sec-0001}
==========

Modelling suggests that additional hepatitis C (HCV) testing of people who inject drugs (PWID) will be required to achieve the WHO HCV elimination target of an 80% reduction in incidence by 2030. We determine the frequency (six-monthly, yearly, two-yearly) and type of testing (HCV antibody/RNA and either lab-based or point-of-care \[POC\]) required among PWID to achieve the HCV incidence reduction target in Australia. We calculate the basic reproduction number to assess whether maintaining this policy would minimise the risk of future outbreaks occurring once the elimination target has been achieved.

Methods {#jve1_14-sec-0002}
=======

Mathematical modelling of HCV transmission among PWID, capturing key steps in the care cascade including prevention, testing, and treatment.

Results {#jve1_14-sec-0003}
=======

Using current estimated rates of loss to follow-up from care, the model suggests that annual POC RNA testing of PWID would be required to reach the HCV incidence reduction target. Both a testing frequency of once-yearly (annual) and a POC RNA test were necessary, since current rates of loss to follow-up prevented high-frequency antibody testing generating enough treatment demand for treatment-as-prevention to be effective, and two-yearly POC RNA testing was not frequent enough to detect new infections before onward transmission could occur. If combined with access to harm reduction services and ongoing access to treatment for all PWID, introducing annual POC RNA testing for PWID entering or engaged in drug treatment was estimated to achieve sufficient testing coverage to reach the incidence reduction target, and minimise the likelihood of future outbreaks of HCV occurring.

Conclusion {#jve1_14-sec-0004}
==========

Increasing the engagement of PWID in care with annual POC RNA testing is required to achieve the WHO HCV incidence reduction target. Combining annual POC RNA testing of PWID with access to harm reduction services and ongoing access to treatment would make future outbreaks of HCV unlikely to occur.

Disclosure of interest statement {#jve1_14-sec-0005}
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Introduction {#jve1_15-sec-0001}
============

Treatment of highly marginalised groups such as people who inject drugs (PWID) and prisoners will be crucial to control of HCV spread. Broad DAA access criteria, including for prisoners, since March 2016 has provided the opportunity to evaluate potential rapid DAA scale-up and its impact at the individual and population levels. Lotus Glen Correctional Centre (LGCC) is located near Mareeba in Far North Queensland and has over 800 beds for male prisoners. A program of rapid DAA scale-up was initiated as part of the 'Make Cairns free of Hep C by 2020' campaign.

Methods {#jve1_15-sec-0002}
=======

Routine bloodborne virus and STI screening is undertaken on entry to LGCC, with more than 95% estimated to be tested for HCV. Nursing staff provide additional assessment for those testing HCV antibody positive, including confirmatory HCV RNA, HCV genotype, and liver disease staging (either Fibroscan or AST to platelet ratio index (APRI) in preparation for treatment. Monthly visits by the hepatitis nurse and doctors from Cairns Sexual Health Service see each of the patients and then treat them with medications supplied via Cairns Hospital. Data was collected on prisoners treated through the DAA program from March 1 2016 to January 31 2017.

Results {#jve1_15-sec-0003}
=======

A total of 94 patients were treated with DAA therapy regimens. 56 had genotype 3/3a and 38 had genotype 1a. Only 2 were considered to have likely cirrhosis via Fibroscan or AST to Platelet Ratio (APRI) scores at commencement of treatment. One prisoner with genotype 3 failed to achieve an SVR and is being re-treated. In early January 2017 there were no further existing patients known to have hepatitis C in the prison.

Conclusion {#jve1_15-sec-0004}
==========

In a regional prison setting with assistance from the local Hospital and Health Service clinical staff, a rapid DAA scale-up program has been successful in reducing the estimated HCV viraemic prevalence from approximately 12% to \<1%. Thus, HCV elimination has been demonstrated, we believe for the first time in a prison setting.
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Background {#jve1_16-sec-0001}
==========

The Eliminate Hepatitis C Partnership aims to increase hepatitis C treatment uptake amongst people who inject drugs (PWID). As little is known about existing service delivery models in community settings we undertook community site scoping to: 1) identify community health and general practice (GP) clinics with high case-loads of PWID, 2) determine their current hepatitis C care models, and 3) develop activity plans to enhance treatment uptake among PWID.

Methods {#jve1_16-sec-0002}
=======

We approached community health and GP clinics, alcohol and other drug services and registered opioid substitution therapy prescribers to be involved in site scoping. We undertook semi-structured interviews in 14 sites, covering hepatitis C screening and diagnosis, liver fibrosis assessment and antiviral treatment.

Results {#jve1_16-sec-0003}
=======

We identified four existing models of care: 1) on-site diagnosis by GPs and referral to a specialist for care, 2) shared care involving a visiting integrated hepatitis nurse and visiting specialist in patient management; 3) integrated hepatitis nurse-led testing and treatment through outreach from an associated specialist hospital (hospital specialist providing paper-check for each patient undergoing treatment), and 4) GPs providing testing and treatment independent of specialists for non-complex cases. Sites often utilised two or more models. For models involving GPs (1 & 4), strengthening referral pathways for liver assessment was seen as important to enhance access to testing and treatment when clients were ready. For models involving hepatitis nurses (2 & 3), capacity to provide opportunistic (point of care, (POC)) testing and increase linkage to treatment was identified as an opportunity.

Conclusion {#jve1_16-sec-0004}
==========

Hepatitis C models of care varied across sites. POC testing, increased resourcing of integrated hepatitis nurse support to community sites and simplified referral pathways to treatment were identified as strategies to maximise hepatitis C testing and treatment uptake among PWID.
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Background {#jve1_17-sec-0001}
==========

Hepatitis B infection in the Indigenous population of the Northern Territory (NT) has an estimated prevalence of 3--12% compared to the national prevalence rate of 1%. There are also significant numbers of people who have never undergone testing and whose serostatus remains unknown. This project aims to identify those who are infected and those who are non-immune and at risk. The project informs the development of targeted health programs.

Methods {#jve1_17-sec-0002}
=======

Data merging of vaccination and serology databases was undertaken and hepatitis B status allocated using serocodes.

The process was piloted on 200 client records; a 16.2% coding inaccuracy detected.

Subsequently we audited 5974 Aboriginal clients' charts, from 5 communities. 1237 records differed from the code generated through data merge.

Serocode fully vaccinated, immune by exposure and chronic infection had an accuracy of \>99%. However an overall inaccuracy of 21% is too high to be useful in a clinical context.

Results {#jve1_17-sec-0003}
=======

90% of this population now have a serocode added to their electronic health record; 67% fully vaccinated, 17% immune by exposure.

10% of the population require follow up as they had no data and 4% are non-immune and were started on vaccination care plans.

123 chronic hepatitis B infections were identified -- 2.3% prevalence of this population; 5.1% prevalence in \>27 year olds (pre universal vaccination cohort).

Six HBsAg positive people were unaware of their diagnosis. Clinicians were advised and hepatitis B care plans commenced.

Conclusion {#jve1_17-sec-0004}
==========

The data merge inaccuracy raises issues for data linkage and automated processes and highlights problems with the quality of data in each system. However it is a useful guide and three codes have high accuracy.

Education opportunities were identified, such as vaccination minimum intervals and serology interpretation. In the NT context, with high staff turnover, sustainable systems and processes are essential to minimise risk.

This project will be expanded to all Top End communities.

Disclosure of interest statement {#jve1_17-sec-0005}
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Introduction {#jve1_18-sec-0001}
============

Direct acting antiviral (DAA) regimens have revolutionised hepatitis C virus (HCV) treatment, with high efficacy and minimal side effects reducing barriers to treatment. Public health strategies have been developed to meet treatment demand, with the ultimate goal of HCV eradication.

Objective {#jve1_18-sec-0002}
=========

To describe characteristics of patients undergoing HCV treatment with DAAs, methods of facilitating treatment, and treatment outcomes.

Methods {#jve1_18-sec-0003}
=======

This was a prospective cohort study of patients treated by Cairns Hospital. Demographics, clinical features (cirrhosis, prior treatment), DAA regimens, and outcomes (sustained virologic response at 12 weeks (SVR12) were recorded.

Results {#jve1_18-sec-0004}
=======

1.  Over a 13 month period, 481 patients received treatment for HCV.

2.  The most common genotypes were genotype 1a (n=226, 47.0%), genotype 3 (n=191, 39.7%) & genotype 1b (n=42, 8.7%).

3.  The most frequently prescribed DAA regimens were sofosbuvir/ledipasvir (n=251 , 52.2%), sofosbuvir/daclatasvir (n=199, 41.4%) & sofosbuvir/ribavirin (n=21, 4.4%). No patients were prescribed interferon.

4.  SVR12 results were available for 77.8% (n=374) of patients treated and demonstrate a SVR12 rate of 96.0% (n=359). Of the patients without SVR12 results, 17.7% (n=85) were lost to follow-up. No patients ceased treatment due to adverse effects.

5.  Presence of cirrhosis (24.3%, n=117) did not independently impact significantly on SVR12 rates (93.8 vs 96.7%, p=0.09)

6.  Treatment experienced patients (n=91, 18.9% of the cohort) were more likely to be non-responders compared to treatment naïve patients (11.3% vs 2.3%, p=\<0.01).

7.  Most prescribers were gastroenterologists (48.6%), general practitioners (24.6%) or sexual health specialists (20.1%).

8.  Diverse strategies to facilitate treatment included a dedicated HCV clinical nurse consultant, education to GP Clinics, specialist outreach clinics to regional communities, and shared-care models with general practitioners.

Conclusion {#jve1_18-sec-0005}
==========

This study demonstrates real-world data confirming high efficacy of DAA regimens in HCV treatment. Diverse models of care facilitate treatment delivery in regional and remote settings.

Disclosure of interest statement {#jve1_18-sec-0006}
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Background {#jve1_19-sec-0001}
==========

The Hepatitis C Treatment and Prevention (TAP) study evaluates the effectiveness of a nurse-led, outreach model to improve hepatitis C treatment uptake by current people who inject drugs (PWID) and their injecting networks.

Method {#jve1_19-sec-0002}
======

PWID are recruited by specialist nurses from a study van in various locations in Melbourne. Primary participants invite their injecting networks to become secondary participants. Referrals come through the SuperMIX cohort, or as self-referrals. Participants are randomly allocated to immediate or deferred treatment with sofosbuvir/velpatasvir. The nurses perform pre-treatment assessments (including elastography) and offer treatment to eligible participants. Follow-up is for 18 months to monitor treatment outcomes, re-infection or resistance to therapy. Social and behavioural data are collected at each visit.

Results {#jve1_19-sec-0003}
=======

316 PWID have been screened, comprising 163 primary and 153 secondary participants. 112 have started and 72 have completed treatment. Some treated participants report an increased sense of well-being and changes in their injecting practices to 'stay clean'. Many have stated that they value the chance to get treatment through the study, as they normally don\'t engage with other health care services. Referral to tertiary health services has been facilitated for those needing treatment outside the study criteria with some degree of success. Eighty-eight participants are screening failures. Mental health issues, homelessness and incarceration impact negatively on being able to attend study visits. Mobile phone numbers change frequently. Finding suitable locations for the van has proven problematic and is dependent on the goodwill of Local Councils and businesses.

Conclusion {#jve1_19-sec-0004}
==========

While homelessness and mental health issues may be obstacles to accessing HCV treatment, we have shown that a nurse-led outreach model provides the opportunity for treatment for many PWID. Its' success relies heavily on existing relationships and continued rapport building with PWID and also on support from local authorities and businesses.

Disclosure of interest statement {#jve1_19-sec-0005}
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Background {#jve1_20-sec-0001}
==========

High rates of efficacy were observed in Co-STAR, a Phase 3 trial of 12 weeks of elbasvir/grazoprevir (EBR; NS5A inhibitor) / (GZR; NS3/4A protease inhibitor) in patients on opioid agonist therapy (OAT). HCV reinfection was observed in 6/296 (2%) of patients between the end of treatment (EOT) and follow-up week 24. The aim of the Co-STAR Three Year Follow-up Study (3YFU) is to evaluate HCV reinfection and injecting risk behaviours in patients treated with EBR/GZR.

Methods {#jve1_20-sec-0002}
=======

This 3 year observational cohort study enrolled patients who received at least one dose of EBR/GZR in the Phase 3 trial. Every 6 months, patients are tested for HCV RNA and if detected, viral genotype and sequencing are performed.

Results {#jve1_20-sec-0003}
=======

Of 296 patients treated in Co-STAR, 185 patients (63%) were enrolled in the 3YFU. Enrolled patients were generally representative of the parent trial. Sixty percent of patients in the 3YFU study had a positive urine drug screen (UDS) at enrolment. The median time from EOT to the first visit during the 3YFU was 330 days (range: 206--485). Other than the 6 reinfections, two viral recurrences were identified at the first visit in the 3YFU. One patient had GT1a at baseline and GT3 at follow-up, opiates and cannabinoids were detected by UDS. One patient had GT1b at baseline, a HCV RNA (258 IU/mL) detected at the first visit; however, the genotype was unable to be determined (low viral load), no drugs besides OAT were detected by UDS; this patient is not considered a reinfection while additional follow-up is pending. Of the 185 patients in the 3YFU, 108 (58%) reported any drug use (non-injecting or injecting) in the past 6 months. Injecting drug use in the past 6 months was reported by 47 (25%) patients. Of those reporting injecting drug use in the past 6 months, injected drugs included heroin (n=34; 72%), amphetamines (n=8; 17%), cocaine (n=7; 15%), and other opioids (n=7; 15%).

Conclusion {#jve1_20-sec-0004}
==========

HCV reinfection among patients on OAT following EBR/GZR treatment is uncommon despite ongoing drug use. Additional follow-up is ongoing.
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Background {#jve1_23-sec-0001}
==========

Over 250 million people worldwide are chronically infected with hepatitis B and even though a prophylactic vaccine and effective antiviral therapies are available, no cure currently exists. Recent advances in the field, such as the identification of the NTCP receptor for viral entry and improved cell culture and animal models, are facilitating a new era in HBV cure research worldwide. However, prior to 2016 coordinated global approaches to HBV cure were non-existent.

Methods {#jve1_23-sec-0002}
=======

The International Coalition to Eliminate Hepatitis B (ICE-HBV) was created in 2016 to accelerate HBV cure research. ICE-HBV aims to support discovery of a safe, affordable, scalable and effective cure, available to all persons living with CHB including children. ICE-HBV\'s vision is to develop an international, independent, research-based and patient-centred forum in order to coordinate, promote and foster collaborative partnerships working towards a cure for HBV.

Results {#jve1_23-sec-0003}
=======

International working groups on virology, immunology, innovative tools and clinical studies composed of leading HBV research experts from around the world have been created to identify HBV cure research gaps and perform the research needed to address these gaps. They are preparing scientific recommendations to inform long-term research policy and programming in order to accelerate the optimization of diagnostics and treatment regimens. These groups engage regularly with key HBV research stakeholders.

Conclusion {#jve1_23-sec-0004}
==========

A global collaborative approach to HBV cure, using science-driven and patient-focused approach, has never occurred before. The ICE-HBV scientific working groups collaborate closely with representatives from key HBV cure stakeholders, including patient representatives, to ensure that their interests and needs are addressed by researchers. Coupled with the implementation of WHO Global Health Sector Strategy on Viral Hepatitis, an HBV cure could help fully eliminate Hepatitis B as a public health problem within the 21st century.
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Background {#jve1_24-sec-0001}
==========

The aim of this study was to assess the characteristics of people who inject drugs (PWID), and evaluate common co-morbidities among current PWID and non-PWID with a hepatitis C virus (HCV) notification in NSW.

Methods {#jve1_24-sec-0002}
=======

HCV notifications 1993--2012 were linked to hospital admission data 2000--2014. Injecting drug use (IDU)-related admissions were defined by hospitalisation due to injectable drugs and/or injecting-related infectious disease.

Results {#jve1_24-sec-0003}
=======

Study population comprised 95,005 people with an HCV notification, 32% (n=30,702) of whom had no episode of hospitalisation, and 68% (n=64,303) were hospitalised at least once during the study period. Among those with a recorded hospital admission, 28,468 individuals never received opioid substitution therapy (OST), and had no IDU-related admission (group 1), 13,180 people had no history of OST, but at least one IDU-related admission (group 2), and 17,399 people had a history of OST and at least one IDU-related admission (group 3). Current PWID included individuals in groups 2 and 3. Group 1 had the oldest age distribution (median birth year 1962, IQR 1956--1970); drug-, liver-, and alcohol use disorder-related admissions comprised \<1%, 6%, and 3% of hospitalisations in this population, respectively. In group 2, median birth year was 1965 (IQR 1956--1973); drug, liver-, and alcohol use disorder-related admissions comprised 5%, 5%, and 7% of their hospitalisations, respectively. Group 3 had the youngest age distribution (median birth year 1971, IQR 1964--1978); drug-, liver-, and alcohol use disorder-related admissions comprised 17%, 3%, and 5% of hospitalisations in this population, respectively.

Conclusions {#jve1_24-sec-0004}
===========

People with HCV infection have high levels of co-morbidities. Hospitalisation could be utilised for enhanced HCV RNA screening/confirmatory testing and consideration for HCV treatment commencement, particularly for more marginalised current PWID with longer planned inpatient care for injecting-related infectious diseases.

Disclosure of interest statement {#jve1_24-sec-0005}
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Introduction {#jve1_25-sec-0001}
============

Key objectives of Australia\'s National Hepatitis B Strategy 2014--2017 include increasing the proportion of people living with chronic HBV (CHB) who have been diagnosed, increasing treatment uptake in those affected, and reducing the burden of attributable morbidity and mortality. Measuring progress towards these objectives through the use of associated indicators and targets allows for identification of appropriate interventions, and assessment of progress over time in order to shape the public health and policy response to hepatitis B in Australia.

Methods {#jve1_25-sec-0002}
=======

We extended an age-structured mathematical model for the transmission and progression of HBV in order to produce more robust estimates of the current burden of CHB in Australia, using a wide range of data sources. The model provides updated estimates for: (i) the number of people living with CHB, (ii) the proportion of people living with CHB that have not been diagnosed, and (iii) the burden of disease and deaths attributable to chronic hepatitis B in Australia.

Results {#jve1_25-sec-0003}
=======

The current prevalence of CHB remains around 1% of the population, however, the number of people living with CHB in Australia continues to increase due to the impact of migration. In order to reduce the number of people affected by adverse outcomes of CHB in Australia, treatment and monitoring needs to continue to increase.

Conclusion {#jve1_25-sec-0004}
==========

The burden of CHB in Australia remains significant, and the proportion diagnosed is still well below National Strategy targets. This analysis highlights the importance of continuing initiatives which aim to increase access to screening, care and treatment for individuals affected. This in turn will contribute to increasing the proportion of people living with CHB who are diagnosed and reducing the overall burden of disease.
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================================

None to disclose.

O25 'Many hands make light work': upskilling the workforce for hepatitis C elimination

Richmond

JA

Burnet Institute, Melbourne, Australia and La Trobe University, Australian Research Centre in Sex, Health and Society

,

Melbourne

,

Australia

The next four years are critical in terms of leveraging the Commonwealth government\'s commitment to fund hepatitis C direct acting antivirals (DAA) and achieve the health minister\'s aim of eliminating hepatitis C infection as a public health threat in Australia. Over the last 30 years hepatitis C treatment has been led by specialist, tertiary-based services, with little input from primary care services. However, in order to achieve hepatitis C elimination, a whole of health system approach is required to integrate hepatitis C treatment within the primary care and community sectors. One of the principal components of the response must be upskilling the health workforce on hepatitis C. We know that one model of service delivery or one community engagement strategy is not enough. People living with hepatitis C are a diverse population who access a range of services. There needs to be multiple points of access to hepatitis C treatment. Integrating hepatitis C into the health workforce\'s scope of practice beyond the realm of individual and organisational early adopters is challenging. Within each professional group there is a need to tailor the information specific to the professional context. Hepatitis C champions need to be identified and supported to lead the expansion of their profession\'s role and to motivate action and challenge inaction. There must be a range of educational options for health workers ranging from one-off learning opportunities to ongoing mentoring and communities of practice. Sustainability requires that the delivery of education and provision of supportive resources allows the information to be retained and recalled quickly, recognising that many workers will have long periods without any contact with people with hepatitis C. The opportunities and challenges presented by upskilling the hepatitis C capacity of the health workforce will be explored in this presentation.
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Introduction {#jve1_36-sec-0001}
============

Primary care based chronic hepatitis C (HCV) treatment is vital to rapidly up-scale treatment numbers in Australia. The PBS listing of Direct Acting Agents (DAA\'s), in March 2016, enabling all primary care practitioners to prescribe via S85 authority scripts was a landmark moment. In February 2016, a viral hepatitis clinic was established, one day per week, in a busy rural NSW general practice by an experienced S100 GP prescriber working closely with local gastroenterologists. Her scope of practice includes co-managing many complicated cases with cirrhosis and advanced liver disease due to the sparsity of gastroenterology services in the region.

Methods {#jve1_36-sec-0002}
=======

Prospective data has been collected on all new HCV cases seen since March 2016 including source of referral, age, gender, genotype, viral load, prior treatment, significant medical problems, APRI, fibroscan, FIB4, cirrhosis status, DAA regime, treatment uptake, adverse events, sustained virological response (SVR), opiate replacement and Aboriginal and Torres Strait Islander (ATSI) status.

Results {#jve1_36-sec-0003}
=======

Preliminary data review from the first 14 months reveal 117 cases have commenced on DAA treatment with approximately 33 % having cirrhosis pretreatment, 14% prescribed opiate replacement and 18 % identifying as ATSI. To date 51 cases achieved an SVR, 4 have relapsed (2 decompensated cirrhosis pre-treatment and 2 non-cirrhotic, GT3a, treatment experienced, null or partial responders to pegylated Interferon treatment), 36 have completed treatment are awaiting 12-week post treatment testing, and 22 are currently on treatment. Detailed data from the first 15 months of operation will be presented.

Conclusion {#jve1_36-sec-0004}
==========

Chronic HCV treatment with DAA\'s is ideally suited to primary care but outcome data is sparse in Australia. This data will assist to compare treatment outcomes with other models of care and be valuable as it includes rural primary and shared care data including many cirrhotic patients.
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Introduction {#jve1_28-sec-0001}
============

More than 60,000 Australians are incarcerated annually and almost 50% report injecting drug use. Hence, both chronic HCV prevalence and HCV transmission rates in the prisons are high. Health care in prisons is challenging as they feature overcrowding, uncontrolled exposure to violence and illicit drugs, lack of purposeful activity, separation from family networks and emotional deprivation. Nevertheless, the recent PBS listing of direct acting antivirals (DAAs) with specific access for prisoners provides a unique opportunity for HCV treatment scale-up.

Methods and Results {#jve1_28-sec-0002}
===================

With regard to the elimination goal of a 90% reduction in incidence, recent data from the Hepatitis C Incidence and Transmission Study in prisons (HITS-p) revealed an HCV incidence of 11%, with no evidence of a decline between 2005 and 2014, associated with high rates of sharing, and regardless of OST provision. These findings argue for new prevention approaches. The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study is examining rapid scale-up of DAA treatment as prevention in four NSW prisons. With over 1400 inmates enrolled in the Surveillance Phase and ongoing incident infections documented, the Treatment Phase is now underway.

With regard to the target of an 80% reduction in chronic HCV, the key obstacle is simplified and efficient health service delivery to ensure engagement and retention in the care cascade. The prisons in most states and territories are offering hepatitis treatment services -- largely via nurse-led models of care. In the first 12 months of DAAs, more than 1000 inmates were initiated on therapy, representing 3% of the national total, and scale up is continuing.

Conclusion {#jve1_28-sec-0003}
==========

The prison sector is well underway in facilitating achievement of the elimination goals. Both expansion, and improved efficiency, of the prison hepatitis health services across Australia will be required to ensure ongoing scale-up of treatment, including for prevention.
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Introduction {#jve1_29-sec-0001}
============

The number of people being monitored and treated for Chronic Hepatitis B (CHB) is falling well short of National Strategy targets and for hepatitis C the initial burst of prescribing post release of the DAAs is over and the challenge is now to offer cure to people outside hospital services. General practice and the broader primary care system and consumers need to be educated, activated and empowered to participate in the elimination of hepatitis as a public health concern by 2030.

Discussion {#jve1_29-sec-0002}
==========

The evidence from Australia and overseas is clear that outcomes for hepatitis C cure in the community can match those of specialist services. The disruptive innovation of the PBS listing in March 2016 and the novel 'in consultation requirement' has shifted the paradigm creating new opportunities of better integration and communication in the health system. CHB care is falling behind under the current traditional model and we need to reimagine how health access can be reconfigured for the 80% of people not receiving monitoring or treatment.

Conclusion {#jve1_29-sec-0003}
==========

Challenges ahead in primary care need adequate funding and resourcing. Partnerships with the community is essential and will strengthen the chance of elimination.
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================================

None declared

O29 Health promotion as a tool to engage marginalised populations

Gorton

CZ

1

Clark

K

2

Lewis

R

1

Bassett

F

1

Henning

J

1

3

Cairns Sexual Health Service

,

Australia

,

Cairns Hepatitis Action Team

,

Australia

,

Curtin University

,

Australia

Introduction {#jve1_30-sec-0001}
============

The availability of direct acting antivirals (DAA\'s) to treat hepatitis C (HCV) has raised the possibility of elimination of HCV if enough people within a population can be treated to reduce new infections.

The new DAA\'s have required a change to business as usual with expanded treatment pathway options via general practitioners, nurse practitioners and primary care services. This change provides an opportunity to embed health promotion frameworks which emphasise equity and social justice principles and address social stigma and system barriers.

Health promotion as a tool to engage marginalised populations involves empowering and creating space for advocates, peers and community members to be central to HCV elimination strategies.

This presentation will focus upon the social determinants of health approach taken by the Cairns and Hinterland region to strengthen supportive and enabling environments for hepatitis C elimination. Dedicated staffing, community development, advocacy, engagement and clinical outreach work across the region provided a strong foundation from 2000 to

March 2016 when the new DAA\'s became available and treatment was transformed.

A broad based health promotion campaign was designed in late 2015 around the themes of 'Cairns Hep C Free by 2020' and 'Take the C out of injection' and coordinated efforts across a range of settings including the local prison, general practitioners, the hospital liver clinic, opioid substitution therapy clients, needle and syringe programs and other services who engage with people who inject drugs have been implemented.

Community advocates and peers with lived experience of chronic HCV and treatments, many as part of the Cairns Hepatitis Action Team, were pivotal to the campaign formulation and implementation.

A 'collective impact' approach has been facilitated by Cairns Sexual Health Service to build a common agenda and shared vision for change.
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Introduction {#jve1_31-sec-0001}
============

The 'Make Cairns Hep C Free' campaign started in early 2016 after the announcement that Direct-Acting Agents against hepatitis C would be available from 1 March 2016 on the Pharmaceutical Benefits Scheme.

Methods {#jve1_31-sec-0002}
=======

Education and treatment provision centred on working with general practitioners and primary care providers to clear the waiting list for the liver clinic at Cairns Hospital, treating those coinfected with HIV, and clearing high prevalence areas such as Lotus Glen Correctional Centre in Mareeba, and those on the local opiate substitution program. In addition treatment at general practices was encouraged and augmented though the use of academic detailing of the new hepatitis C medications. The physician outreach team to Cape York and Torres Strait also started treating known people in that vast geographic area. The local community of people living with hepatitis C, and injecting drug users was also mobilised.

Results {#jve1_31-sec-0003}
=======

Within the first 12 months of access to the new hepatitis C treatments the liver clinic had arranged treatment for all people attending that clinic and known to have hepatitis C, the sexual health service had treated all those coinfected with hepatitis C along with any others attending the service, the prison and opiate substitution program had treated all those known to have hepatitis C, and many general practices had also treated all their known patients. Cape York and Torres Strait were also cleared of known hepatitis C cases.

Conclusion {#jve1_31-sec-0004}
==========

In a regional setting it is possible to make great inroads into hepatitis C eradication by focussing on ervices with a high prevalence of hepatitis C. Academic detailing of general practices also showed itself to be useful and led to high uptake of treatments in the community. Further work is underway to identify general practice sites that have not yet treated all their patients with hepatitis C, and to further engage clients attending needle and syringe programs.
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Introduction {#jve1_32-sec-0001}
============

Broad community ownership will be key to any successful viral hepatitis elimination program. The approach to community engagement, acceptance and mobilization will vary according to each community\'s history and setting: urban, city, rural or remote. There is no one formula. Engagement begins with doing 'homework': investigating the community makeup, languages, culture, background history, geography, weather, infrastructure and leadership. An initial community visit should typically entail unhurried and respectful listening. Visitors should seek guidance from the locals about core cultural matters. Any offer of additional service provision and healthcare capacity-building will be welcomed.

Wide consultation is essential. This would start with the community health service: the manager, health workers, nurses, doctors and allied health team. Support of health workers will be critical. Consultation can then continue with the Community Council, Health Council or Action Team, Community Justice Group, Women\'s group, Wellbeing Centre, sports teams, Arts Centre, schools, local religious leaders, and parole and probation officer\[s\]. It will be important to establish dates of scheduled community events plus being aware of unscheduled events \[funerals\].

Visitors should be mindful that HBV and HCV infections make up only a fraction of a much wider community health burden. There are many common social determinants; the burgeoning rate of incarceration is of particular concern. The capacity of primary healthcare to address chronic illness has radically expanded in the last two decades and a hepatitis elimination program can be directed from the community health service. Effective delivery will depend on cultural safety and continuity of care; that\'s where local health workers are so important. Gaining truly informed consent is always a challenge, as is keeping track of people in a highly mobile population.

Long-lasting and trusting relationship is essential for 'effective community healthcare. This requires cultural respect, continued engagement, flexibility and recognition of people\'s autonomy.
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Introduction {#jve1_37-sec-0001}
============

It is easier to default to the 'problem' of hepatitis B and C in our communities, rather than thinking of the aspirations, connections, and resources of community members living with viral hepatitis. The emerging success of our local campaign 'Hep C Free by 2020' is in part due to a strength based approach to community engagement adhering to core principles of health promotion. Engagement must be real, reciprocal, and share the power and the resources in order to reap the benefits of larger treatment numbers; access to hidden at risk community members; informed, refined, targeted, appropriate and therefore cost effective service delivery.

The Cairns Hepatitis Action Team (CHAT) was established as a communication pathway between clinical services and community members; a lobby and action group; a safe space for friendships and personal growth. The members were invited and self-selected (some as graduates from the Hep C Support Group) for their interest in being out to the public, sharing their stories of resilience and survival, reducing stigma, and increasing access to care for people living with viral hepatitis.

On a practical level these principles of engaging community mean paying and resourcing community members for their time, their training needs, and their expertise (funding and supporting conference attendance, sharing speaking space at conferences with community members, paying community members as positive speakers, reimbursing community members for travel costs, and supporting community members in their career goals). The CHAT example shows that this can easily be achieved within services' usual budgets, and with the support of staff members driving the process.

The CHAT example reflects Ottawa Charter principles in a real world setting, empowering individuals and communities to access and create their own opportunities to educate, whilst developing personal skills, strengthening community action, re-orienting health services, and building collaborative healthy public policy.
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================================

No conflicts of interest*.*

O33 Health systems requirements for hepatitis elimination: are we 'flying blind' in our efforts

Lazarus

Jeffrey V

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona

,

Spain

and

CHIP, Rigshospitalet, University of Copenhagen

,

Denmark

Introduction {#jve1_33-sec-0001}
============

The World Health Organization (WHO) published its first-ever *Global Hepatitis Report* in April 2017. Only about 20% of people with chronic hepatitis C virus (HCV) are thought to be aware of their disease, and only a small fraction of those diagnosed are receiving treatment. WHO describes these and global hepatitis B virus (HBV) estimates as 'preliminary'.

To remedy the situation, national governments need to do much more to meet their monitoring responsibilities in relation to viral hepatitis, a group of diseases that claims more lives annually than HIV does. Without reliable information about the extent of the problem, and about the impact of interventions to mitigate the problem, it is not possible for health systems to determine how to best allocate their always-limited resources. Large knowledge gaps regarding disease epidemiology and intervention coverage may seem to be characteristic of resource-limited countries. However, some of the most affluent countries in the world are unprepared to carry out the kind of evidence-based decision-making that will be required to achieve the goal of eliminating viral hepatitis as a public health threat by 2030.

This problem is partly reflective of how HBV and HCV infection manifest -- often with a decades-long asymptomatic period during which liver deterioration progresses unnoticed. Yet monitoring both diseases is not the greatest obstacle to progress against the global HBV and HCV epidemics. The greatest obstacle is government inaction, as reflected by the fact that globally only 43 WHO Member States even reported having viral hepatitis strategies or plans as of March 2017. Eliminating HBV and HCV as a public health threat is feasible, as is the full elimination of both diseases -- but only with greater attention to health systems. This presentation will review the main components of a people-centred health systems approach to viral hepatitis elimination.
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Major progress has been made in viral hepatitis over the past few years. Global targets have been announced for the elimination of viral hepatitis as a public health threat. Global treatment guidelines for treatment for hepatitis B and hepatitis C have been released, as have guidelines for viral hepatitis testing. Most recently WHO released the Global Hepatitis Report providing an important overview of the current global situation. Country plans are being developed, new innovative testing programs are being implemented and treatment scale up has begun in many countries. The price of treatment has begun to fall. But in many respects these achievements are just the beginning. They are the tools to help us along a path to elimination over the next 10--15 years.

Success will only come if we work together -- community, government, NGOs, clinicians and health service provides researchers, civil society, companies, and funders. We all need to engage with each other and work together. A strategic multipronged approach of prevention, testing and treatment is required. This presentation will highlight the way forward, highlighting future challenges and opportunities as we strive to achieve the 2030 elimination targets.
